Search research articles
Contact Us
Filters
Showing results (1-10 of 260) with videos related to
Page
of 26
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
April 22, 2025
The development of ATR inhibitors
Timothy A Yap
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 19, 2016
Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?
Timothy A Yap, Sanjay Popat
Expert Opinion on Drug Metabolism & Toxicology
|
August 30, 2013
The role of afatinib in the management of non-small cell lung carcinoma
Timothy A Yap, Sanjay Popat
The Oncologist
|
October 18, 2017
Development of Molecularly Driven Targeted Combination Strategies
Timothy A Yap, Jordi Rodon
Annual Review of Pharmacology and Toxicology
|
January 13, 2012
Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics
Timothy A Yap, Paul Workman
Pharmacogenomics and Personalized Medicine
|
October 4, 2014
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
Timothy A Yap, Sanjay Popat
Current Problems in Cancer
|
April 5, 2017
Precision medicine in oncology
Naoko Takebe, Timothy A Yap
Cancer Journal (Sudbury, Mass.)
|
December 14, 2021
The Principles and Practice of PARP Inhibitor Therapy
Timothy A Yap, Robert L Coleman
Clinical Genitourinary Cancer
|
October 10, 2006
Adjuvant therapy of renal cell carcinoma
Timothy A Yap, Tim G Eisen
Clinical and Translational Medicine
|
July 17, 2025
Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy
Tejaswini P Reddy, Timothy A Yap
Page
of 26
Search research articles
Search
Showing results (1-10 of 260) with videos related to
Sort By:
Page
of 26
Clinical Advances in Hematology & Oncology : H&O
|
April 22, 2025
The development of ATR inhibitors
Timothy A Yap
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 19, 2016
Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?
Timothy A Yap, Sanjay Popat
Expert Opinion on Drug Metabolism & Toxicology
|
August 30, 2013
The role of afatinib in the management of non-small cell lung carcinoma
Timothy A Yap, Sanjay Popat
The Oncologist
|
October 18, 2017
Development of Molecularly Driven Targeted Combination Strategies
Timothy A Yap, Jordi Rodon
Annual Review of Pharmacology and Toxicology
|
January 13, 2012
Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics
Timothy A Yap, Paul Workman
Pharmacogenomics and Personalized Medicine
|
October 4, 2014
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
Timothy A Yap, Sanjay Popat
Current Problems in Cancer
|
April 5, 2017
Precision medicine in oncology
Naoko Takebe, Timothy A Yap
Cancer Journal (Sudbury, Mass.)
|
December 14, 2021
The Principles and Practice of PARP Inhibitor Therapy
Timothy A Yap, Robert L Coleman
Clinical Genitourinary Cancer
|
October 10, 2006
Adjuvant therapy of renal cell carcinoma
Timothy A Yap, Tim G Eisen
Clinical and Translational Medicine
|
July 17, 2025
Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy
Tejaswini P Reddy, Timothy A Yap
Page
of 26